Revenue +24% Can't Hide Profit Collapse; Thailand Turnaround Unproven
Styrenix delivered headline revenue growth of 24.4%, but consolidated PAT crashed 48.2% as its Thai subsidiary bled nearly ₹28 crore in a single quarter. The core India business remains strong—but the consolidated result is the real profit.
₹23.2 Cr
-48.2% YoY
₹51.2 Cr
profitable
~₹28 Cr
7 quarters cumulative >₹200 Cr
The quarter sits on a schism: India's polystyrene business delivered ₹51.2 crore in net profit, but the company's Thai subsidiary bled nearly ₹28 crore in the same quarter, leaving consolidated PAT at just ₹23.2 crore. That ₹28 crore loss wasn't a one-time charge — it reflects seven consecutive quarters of red ink since the Thai acquisition in January 2025. The revenue jumped 24.4% because India volumes recovered and new ABS grades came to market. The profit didn't recover because that growth is being reinvested into capacity expansion, and the Thai turnaround is proving far slower—and far costlier—than the board indicated when it closed the deal.
Where the profit went — and what holds up
ABS volumes up; capacity utilization improving
ABS volumes recovered in Q2. But consolidated PAT collapsed 48.2% despite revenue up 24.4%. Gains entirely offset by Thailand.
Supported (but masked)
India margins improving through cost management and volume ramp
India standalone PAT ₹51.2 Cr positive and stable. Consolidated NPM 2.3% vs prior year reflects Thailand drag—margin compression visible at group level.
Overstated at group level
Phase 1 ABS expansion expected operational by end of FY27
On track for Q3–Q4 completion. But capex timing vague—Jan–March 2027 window confirmed by CFO. Ramp-up lag of 1–2 quarters acknowledged.
Partial — timeline reaffirmed, utilization path not
Thailand will be structurally profitable; trajectory improving over next two years
Seven consecutive loss-making quarters. Management says 'two years' to profitability but provides zero operational milestones, KPIs, or near-term bridge.
Overstated — unsubstantiated timeline
New ABS grades (ASALAC, STYROLOY) expanding addressable market
Grades launched and approvals underway. Volume ramp gradual. No quantified market uplift or margin uplift timeline yet.
Supported but early-stage
What changed on this call
Thailand consolidation now visible in the PAT. Prior results masked small Thai losses buried in the aggregate; now the ₹28 crore quarterly drag sits front-and-centre. This is not an accounting reclass—it's a real cash loss that the India business can no longer hide.
Polystyrene volumes consciously reduced. Management made an active call to avoid chasing non-OEM GPPS demand in Q2 due to price volatility. This signals defensive margin protection rather than growth opportunism—a tacit admission that the commodity segment is weakening.
ABS capex timeline remains vague on utilization. 'End of FY27' reaffirmed, but the CFO was pressed on the month and gave Jan–March 2027 window with acknowledgment of ramp-up lag. No clarity on when Phase 1 hits 80%+ utilization or starts contributing material EBITDA.
New specialty grades are concrete but gradual. ASALAC and STYROLOY have launched; approvals are underway for automotive and appliance segments. This is a real structural lever, not promotional rhetoric—but ramp will take 2–3 quarters to materialize as volume and margin contribution.
ABS capacity expansion on track and real (30,000–40,000 tons/year incremental)
India business stable and genuinely profitable (₹51.2 Cr Q2 PAT)
New specialty grades (ASALAC, STYROLOY) address growing EV/automotive segments
Unique refrigeration-liner ABS grade provides local competitive moat
Consolidated PAT collapsed 48.2% YoY despite revenue up 24.4%
Thailand quarterly loss ~₹28 Cr now visible; 7-quarter cumulative loss exceeds ₹200 Cr
'Two-year turnaround' stated with no operational milestones, capex scaling KPIs, or credible near-term bridge
QoQ PAT down 83.2%; Q1–Q2 cliff reflects seasonality + polystyrene margin collapse + Thailand costs
Polystyrene demand defensive; management skipped non-OEM GPPS volumes in Q2
Raw material volatility (styrene ₹1300–₹1700 range) limits finished product pricing power and margin recovery pace
Thailand turnaround delayed beyond management's 2–3 year estimate
HighSeven consecutive loss-making quarters; cumulative losses >₹200 Cr already. If cost structure is stickier or demand recovery slower than 'two years,' cash burn accelerates, balance sheet pressure increases, and strategic optionality erodes. No public operational milestones to validate progress.
Raw material volatility and margin pass-through lag
HighStyrene monomer ₹1300–₹1700 range; formula-based customer pricing lags 1–2 quarters. Q2 NPM 2.3% vs prior year reflects this lag despite volume recovery. If input costs remain elevated, margin recovery timeline extends, pushing payback on new capex further out.
New ABS capacity ramp-up slower than expected
MediumPhase 1 capex expected Jan–March 2027, but CFO acknowledged ramp-up lag of 1–2 quarters for full utilization. If customer approvals or demand absorption is slower, or if competitive intensity pressures pricing, EBITDA uplift from new capacity delays further, pushing Thailand breakeven timeline back.
Polystyrene demand weakness persists or accelerates
MediumNon-OEM GPPS demand weak in Q2; management made active call to avoid low-margin spot volumes. If appliance cycles and packaging demand further deteriorate on macro slowdown, India's HIPS/GPPS revenue base faces volume pressure, offsetting ABS growth and prolonging margin recovery.
Competitive intensity from Korean and Taiwanese ABS capacity ramp-up
MediumNew entrants bringing regional ABS capacity online. Specialty grades provide some insulation, but if commoditized ABS pricing pressure accelerates faster than Styrenix can ramp high-margin grades, margin accretion from new capacity is delayed or eroded.
Capex project execution delays or cost overruns
MediumMD said completion is 'very close'; CFO gave Jan–March window when pressed, but analyst skepticism evident. Any project delays push EBITDA upside into FY28, extending turnaround narrative and further testing market patience and FII appetite.
How the street is reading this
The market's post-result reaction tells the story. On the day of announcement, the stock dipped 0.39%, with delivery at 66.7%. By day 3, it had fallen 2.81%—a fade that persisted into day 5 with only a 0.44% rebound. That is not the tape of a market convinced by the revenue growth story when consolidated profit is contracting 48.2%.
Institutional flows confirm the skepticism. Foreign institutional investors have trimmed holdings from 0.95% in Q4 FY-2026 to 0.86% in Q1 FY-2027—a net sell signal from the most rate-sensitive cohort. Domestic institutions have held steady at 17.44%, neither adding nor aggressively cutting, suggesting a 'wait-and-see' posture. Meanwhile, the stock is down 48.26% from its all-time high, sitting below its 20-day, 50-day, and 200-day moving averages—a textbook risk-off chart that reflects eroded confidence in the turnaround narrative.
At ₹1,810, the stock is pricing in a prolonged earnings recovery. The market is not hostile, but it is doubtful. That skepticism is justified. The India business is fine; the Thailand acquisition is the structural headwind, and management's timeline for resolution lacks credible near-term operational proof.
1 · Phase 1 ABS capex commissioning and initial utilization (Q3–Q4 FY27 / Jan–March 2027)
Watch for: exact month of go-live, initial production run, and utilization trajectory. If delayed beyond Jan–March or ramps slower than 60–70% utilization in the first quarter post-commissioning, the EBITDA bridge extends into FY28 and Thai turnaround timeline slips further.
2 · Thailand operational metrics and cost structure progress (Q3 FY27 onwards)
Watch for: Thai volume growth, gross margins, and monthly loss trajectory. Hold management accountable on 'two years to profitability' with concrete Q3–Q4 run-rates and cost savings realized. If Q3–Q4 losses remain >₹20 Cr/quarter, the two-year timeline is at material risk.
3 · Raw material pass-through and consolidated net margin recovery (next 2–3 quarters)
Watch for: styrene monomer pricing trends and gross margin Q-o-Q progression. If input costs stabilize and formula-based pricing works through, consolidated NPM should recover from 2.3% toward 5–6% range by Q4 FY27. Failure to recover signals structural margin deterioration.
Styrenix is not a broken company. The India business is genuinely profitable (₹51.2 Cr standalone PAT), and the ABS capacity expansion is real and on track. But the consolidated result—₹23.2 crore PAT on ₹993.5 crore revenue—is the truth. That is a 2.3% net margin on a specialty chemicals portfolio, and it tells you the turnaround is longer and costlier than the board suggested when it acquired Thailand.
The rating is Hold. Not a sell (India is profitable, ABS expansion is real, management is transparent on headwinds), but not a buy until Thailand turnaround shows concrete operational progress and capex ramp-up delivers expected margin accretion. The market's skepticism, reflected in the -0.39% to -2.81% fade and FII trimming, is justified.
The single number to track from here is Q3 FY27 consolidated PAT. If it recovers to >₹40 Cr (moving toward seasonal normal and reflecting early capex contributions), the turnaround narrative regains credibility and multi-year optionality becomes tangible. If it drops further or remains near ₹23 Cr, the hold becomes harder to defend. The India business is not the question—Thailand is. Watch the quarterly loss there; it is the real P&L.
Revenue growth masks PAT collapse; margin recovery hinges on Thailand turnaround
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Guided ABS expansion 'FY27 completion' but no precision given; capex in Jan-Mar window; analyst skepticism on Thailand breakeven timeline warranted.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Styrenix is in a multi-year turnaround: revenue growth and ABS capacity expansion provide long-term upside, but consolidated PAT crashed -48.2% YoY as Thailand losses (acquired Jan 2025) swamped India's INR51.2 Cr profit. Near-term margin recovery hinges on Thailand cost restructuring (2+ years estimated) and raw material volatility easing—both uncertain.
₹993.5 Cr
Revenue · +24.4% YoY₹23.2 Cr
Reported PAT · −48.2% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
ABS volumes up significantly, improving capacity utilization
MISSQ2 ABS sales volume recovered but profit down 48.2% YoY; India PAT INR51.2 Cr vs consolidated INR23 Cr due to Thailand losses
India margin improvement through cost management and HIPS volume growth
OVERSTATEDConsolidated NPM collapsed to 2.3% from prior year; India stand-alone PAT INR51.2 Cr positive but masked by Thailand losses
Phase 1 ABS expansion expected to be operational by end of FY27 with significant EBITDA upside
PartialNo timeline given for commissioning; CFO confirmed capex will go live 'by end of year' but no precision on when capacity will be fully absorbed
Thailand business will be structurally profitable and multi-year trajectory is improving
OVERSTATEDThailand now 7 quarters under management; still loss-making with no clear breakeven timeline; management says 'two years' for improvement, margins still weak
New ABS grades (ASALAC, STYROLOY) expanding addressable market
METGrades launched and approvals ongoing; only gradual volume ramp; no quantified market size or margin benefit provided
Earnings quality
What changed since the last call
Thailand contribution now consolidated; drags PAT visibly
DowngradePrior call (implied H1 FY27 strength with PAT ₹188.5 Cr H1) masked small Thailand losses. Now ₹23.2 Cr consolidated Q2 vs ₹51.2 Cr India standalone reveals ₹28 Cr+ quarterly loss in Thailand. Drag larger than guided 'ramp-up' tone.
Polystyrene demand weaker; GPPS volumes consciously reduced
DowngradeManagement admits choosing NOT to chase non-OEM GPPS demand in Q2 due to price volatility and speculative market. Volumes lower; reflects demand weakness and pricing discipline.
ABS expansion capex timeline remains vague (Q3-Q4 FY27 'commissioning' now, but ramp-up uncertain)
NeutralNo change in stated completion window, but analyst questions on when full utilization happens; CFO confirmed 15–20 day lag for online capacity but no breakeven guidance.
New ABS grades (ASALAC, STYROLOY) launched; approvals ongoing
NewTwo new specialty grades now in market with approvals in progress; expected to drive margin upside post-2027. Concrete mechanism for future positioning but no near-term margin benefit yet.
The Q&A
Analysts pressed hard on Thailand breakeven (Nirav Jimudia: 'two years still not clear, when will demand/cost match?'), capex scale-up (Ronak Chheda: 'how long to hit 100% utilization?'), and competitive intensity (Aditya Khetan: 'competitor plants ramping ABS—why should we win?'). Management held to 'two-year trajectory' and 'cost management' but offered no credible near-term margin bridge. Tone was defensive on Thailand; defensive on polystyrene. Analysts seemed skeptical.
ABS imports, capacity pricing — Nirav Jimudia, Anvil Wealth
AnsweredRefrigeration liner ABS grade (unique in India currently). Can produce ~30,000–40,000 tons annually. Other grades exist but our competitive positioning is in niche refrigeration + automotive segments. Margin advantage from specialization, not volume.
Polystyrene volume ramp-up — Nirav Jimudia, Anvil Wealth
PartialGPPS non-OEM demand uncertain; we chose not to participate in speculative volumes in Q2 due to raw material risk. H2 volumes should be in line with Q2 on annualized basis. Management call—no aggressive volume assumption.
Thailand breakeven timeline — Aditya Khetan, SMIFS Institutional Equities
AnsweredRealistic is 2–2.5 years for profitability given cost structure, product mix rebalancing, and new capacity benefits. China export also not started yet. Business makes sense structurally long-term but near-term patience required.
Gross margin trajectory — Ronak Chheda, Awriga Capital
PartialGross margins on annualized basis align with historical levels if Q1 anomalies removed. Capex will go live by end of FY27, but exact month uncertain (Jan-March window). Scale-up lag of 1–2 quarters for full utilization expected.
New grades, market expansion — Nirav Jimudia, Anvil Wealth
AnsweredBoth. ASALAC for automotive/EV thermal systems + solar. STYROLOY blends for appliances. Approvals in progress; gradual volume ramp expected. Not a volume jump but margin accretion over time.
Thailand product mix, regional demand — Ashwin Reddy, Samatva Investments
AnsweredProduct mix rebalancing ongoing; specialized grades still ramp slowly. Competitive intensity from Korea/Taiwan but local pricing power exists due to specialization. Sales mix: ~40–50% China, ~20–25% Thailand domestic, ~25–35% Japan/Vietnam/other regions.
ABS capacity utilization, competitive positioning — Aditya Khetan, SMIFS Institutional Equities
PartialOur unique positioning is in specialty grades (refrigeration liner, niche appliance grades) where we have limited competition. Commodity grades have less margin but don't compete directly. Volumes will grow gradually, not capture full market.
Market share maintenance — Meet Parekh, Mihir Asia & Corporation
PartialDumping has occurred; import duties removed then reinstated. Local manufacturers still prefer Indian suppliers for quality/consistency. Pricing pressure exists in commodity grades; specialty grades have better pricing power. Market share stable YTD.
Thailand cash loss in Q2 — Meet Parekh, Mihir Asia & Corporation
AnsweredQ2 is near the base case. Product mix rebalancing and cost actions have offset some pressure. Improvements likely in H2 as volume ramp and cost savings take hold, but full recovery is 2+ years.
Volume guidance, FY27-FY28 outlook — Aditya Khetan, SMIFS Institutional Equities
DodgedNo forward-looking guidance on volume targets. Focus is on capacity utilization and margin improvement. New ABS capacity coming online will add incrementally but timeline for full absorption is not given.
Guidance
No explicit FY27/FY28 revenue target provided
LowManagement confirmed Phase 1 ABS expansion 'on track for FY27 completion' (Q3-Q4 timeline) but no volume ramp or revenue uplift quantified.
Gross margins expected to normalize at historical levels post-Q1 anomaly
MediumCFO stated Q2 margins 'slightly better YoY on absolute spread' but acknowledged raw material volatility persists. No NPM recovery timeline given.
ABS expansion to deliver EBITDA upside; timeline unspecified
LowNo margin bridge or EBITDA target stated. Management said 'long-term value' but admits cost reduction in Thailand is 2+ years away.
Phase 1 capex completion by end of FY27 (Jan-March 2027 window)
MediumMD stated 'very close to it' and capex will go live 'by end of year' but exact month uncertain. Ramp-up lag of 1–2 quarters for full utilization.
Risks the call surfaced
Thailand turnaround execution
HighThailand subsidiary 7 quarters post-acquisition with cumulative losses >₹200 Cr (implied). Cost structure fundamentally higher than India; management estimates 2–3 years to profitability. If timeline slips, cash burn accelerates.
Raw material volatility and cost pass-through
HighStyrene monomer prices volatile (₹1300–₹1600 range); management actively avoiding speculative procurement. Formula-based pricing for ABS/HIPS limits upside if input costs spike faster than customer passes through. Q2 NPM 2.3% reflects margin compression despite 24% revenue growth.
New ABS capacity ramp-up execution
MediumPhase 1 capex completion timeline vague (Jan-March FY27); even if on time, full utilization not guaranteed. Analyst skepticism evident: 'will it take 2 years to hit 100% utilization like competitors?' Management offered no utilization roadmap. If ramp is slow, EBITDA upside delays further.
Competitive intensity and import substitution
MediumKorean/Taiwanese competitors ramping ABS capacity in region; China dumping risk documented. Management maintains market share but pricing pressure evident. Commoditized GPPS grades are margin-dilutive; speculative volumes avoided. If regional competitive intensity increases, pricing power erodes.
Polystyrene demand softness
MediumNon-OEM polystyrene demand impacted by macro uncertainty. Management chose NOT to chase speculative GPPS volumes in Q2 due to price volatility and lack of committed demand. If polystyrene customer base further weakens (appliances, packaging), volume recovery delays.
Management
Score 6/10. Transparent on challenges (Thailand losses, polystyrene weakness, raw material volatility). However, vague on timelines: 'FY27 completion' for capex without month precision; '2–3 years' for Thailand breakeven without milestones. Avoids specific numbers on volume guidance. Mixed track record. ABS capacity expansion on stated timeline (reaffirmed prior guidance). Thailand acquisition has delivered cumulative losses >₹200 Cr in 7 quarters—significantly worse than implied turnaround expectations. India business stable; margin management adequate but reactive.
1 · Q3-Q4 FY27
Phase 1 ABS capacity (new refrigeration-liner grade) comes online; margin accretion begins
2 · Next 2-3 years
Thailand cost restructuring complete; operations become structurally profitable per management (unverified timeline)
3 · H2 FY27
New ASALAC and STYROLOY grades ramp volume; high-margin specialization increases
Near-term margin recovery hinges on Thailand cost restructuring (2+ years estimated) and raw material volatility easing—both uncertain.
Styrenix consolidated PAT sinks 48% YoY, 83% QoQ as Thailand unit swings to ₹30 Cr loss
PAT -48.2% YoY · revenue +24.4% · margins compressing
₹993.51 Cr
+24.4% YoY
₹23.17 Cr
-48.2% YoY
2.32%
-3.3pp YoY
₹13.18
Styrenix Performance Materials' consolidated PAT fell 48.2% YoY to ₹23.17 Cr (from ₹44.72 Cr in Q2 FY26) and 83.2% QoQ (from ₹138.30 Cr in Q1 FY27), even as consolidated revenue rose 24.4% YoY to ₹993.51 Cr, though it slipped 1.7% QoQ from ₹1,010.86 Cr. Consolidated EPS fell to ₹13.18 from ₹78.64 in Q1 FY27 and ₹25.43 a year ago. On a standalone (India) basis the picture is materially different: PAT was nearly flat YoY at ₹51.20 Cr (vs ₹50.78 Cr), a greater than 3% divergence from the consolidated YoY move that readers should note — the consolidated miss is driven almost entirely by the Thailand step-down subsidiary swinging to a ₹(29.62) Cr net loss on ₹226.15 Cr of revenue this quarter, reviewed by other auditors per the limited review report; the UAE subsidiary (FZE) is dormant and immaterial.
Q2 FY-2027 vs prior quarters
Margins compressed sharply at the group level: NPM fell to 2.32% from 13.64% in Q1 FY27 and 5.58% a year ago, while OPM (EBITDA excluding other income, over revenue) fell to 7.23% from 21.79% QoQ and 10.70% YoY. Even on a standalone basis, cost of materials consumed rose to 76.4% of revenue this quarter versus roughly 69% in both Q1 FY27 and Q2 FY26 — raw material cost pressure (styrene monomer pricing, flagged by management last quarter as elevated at $1,100–$1,400 versus a pre-war ~$1,000) is outpacing finished-product price pass-through, which management had expected to normalize. Depreciation rose modestly (₹30.36 Cr consolidated vs ₹26.16 Cr YoY) consistent with ongoing ABS capacity expansion capex.
The stock went into the print at ₹1,818, down 12% over the past month of trading.
What the summary numbers don't show
No exceptional items in the current or comparative periods — results approved by the Board on Oct 28, 2026
ABS capacity expansion on track for FY27 completion (Q3–Q4, no precision given). Raw material pricing volatility (styrene monomer $1100–$1400 currently vs $1000 pre-war) to persist; finished product pricing expected to normalize with input costs. Volume recovery timeline uncertain; no numerical guidance provided.
— This quarter: missed
No street estimates for this quarter could be located (small-cap with limited published coverage), so vsStreet is unknown. Against management's own prior commentary — raw material volatility persisting (confirmed) but finished-product pricing normalizing with input costs (not evident this quarter, standalone COGS ratio rose) — the print reads as a miss on the pricing-normalization expectation specifically; the no-numerical-guidance caveat from the last call still applies, so this is a qualitative read, not a hard target comparison. There is no fresh management press release in the record for this result. Among the quarter's other corporate developments, the company received a ₹1.92 Cr tax demand order (25-Sep-26) — immaterial relative to the P&L and not booked as an exceptional item; the ₹23 interim dividend, AGM notice, and BRSR/annual report filings in August are routine and unrelated to this quarter's operating numbers.
W1
Whether the Thailand subsidiary's ₹29.62 Cr quarterly loss is one-off or recurring — next quarter's standalone-vs-consolidated gap will show the trend
W2
Raw material cost trajectory (styrene monomer pricing) and whether finished-product pricing catches up, as management previously guided it would
W3
ABS capacity expansion progress against management's Q3–Q4 FY27 completion timeline, visible via CWIP (₹181–185 Cr) converting to operating assets